San Diego, United States
OncoSec is a biotechnology company founded in 2011, aiming to revolutionize cancer treatment by leveraging innovative technologies to activate the body’s immune system against cancer cells. The company's proprietary DNA gene transfer technology, including TAVO™, an intratumoral (IT) DNA plasmid-based interleukin-12 (IL-12), has shown promising results in clinical trials for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC).
OncoSec's breakthrough technology, TAVO, has been granted Orphan Drug and Fast-Track Designation by the U.S. Food & Drug Administration for its efficacy in metastatic melanoma. This recognition underscores the potential of OncoSec's approach in addressing unmet medical needs for patients with limited or no treatment options.
The company's recent NASDAQ listing under the symbol $ONCS has marked a significant milestone. On 16 May 2023, a Post-IPO Equity investment was secured, signifying investor confidence in OncoSec's innovative biotechnology solutions.
OncoSec's dedication to advancing DNA-encoded therapeutic candidates and targeting various cancer indications indicates a promising trajectory for the company's future growth and impact in the realm of cancer treatment.
